| | | |

Radiation for Mesothelioma: Could Proton Therapy Be the Answer?

Researchers at the Maryland Proton Therapy Treatment Center say a highly-targeted version of proton beam radiation could be the future of radiotherapy for malignant pleural mesothelioma.

In a new journal article, doctors at the center detail the evolution of radiation treatment for pleural mesothelioma, from standard photon-based therapy to targeted proton therapy.

“Radiation therapy has historically been used [for mesothelioma] only in the palliative setting or as adjuvant therapy after extrapleural pneumonectomy,” notes the report.

But the researchers go on to say that radiotherapy advances such as intensity-modulated radiation therapy (IMRT) and a more precise form of proton beam therapy called pencil-beam scanning, are changing the value of radiotherapy for mesothelioma patients.

Radiation’s Role in Pleural Mesothelioma Treatment

Radiation works to kill cancer cells by permanently damaging the DNA that is their roadmap for growth, metabolism, and replication. When the DNA molecules are too scrambled to direct the life of the mesothelioma cell, the cell dies. If enough cells die, a tumor can be destroyed.

The challenge in radiotherapy is always how to target the tumor with sufficient amounts of cell-destroying radiation, without simultaneously damaging healthy surrounding tissue.

 

While targeted radiotherapy can be an effective treatment for certain types of tumors, the challenge for people with malignant mesothelioma is that 1) mesothelioma tumors are not uniform in size or shape and 2) pleural mesothelioma tumors lie close to other critical organs like the lungs and heart.

This is why even targeted radiotherapy systems like IMRT have primarily been used to slow down pleural mesothelioma tumor growth prior to surgery, to help control mesothelioma symptoms, or to destroy residual mesothelioma cells after surgery.

Proton Beam Therapy Could Change Mesothelioma Care

Proton Beam Therapy is the “new kid” on the radiotherapy block. Although the technology has existed for decades, it is only in the last few years that it has begun to get more attention from the cancer community as a potential treatment option.

Like photon-based radiotherapy, proton-based radiotherapy uses ionizing radiation to kill cancer cells and shrink tumors. But some studies have suggested that protons may be safer than photons.

Because they tend to lose energy more quickly as they slow down on their way through tissue, the theory is that protons make it possible to deposit a higher dose of radiation into a mesothelioma tumor without damaging healthy tissue around it. Research has produced mixed results.

The newest study from the Maryland Proton Treatment Center focuses on a particular type of proton therapy called pencil beam scanning (PBS) in the treatment of pleural mesothelioma tumors..

While standard proton therapy treats the entire tumor with the same dose of protons at the same time, PBS allows the doctor to adjust the intensity of the beam for each layer of the mesothelioma tumor. Magnets are used to focus the beam, allowing for higher dosing in areas that need it.

The researchers say the added safety and precision of PBS make it possible to use it “as definitive therapy for patients with recurrent or unresectable disease.”

“PBS proton therapy has the potential to deliver high doses of irradiation to the entire effected pleura while significantly reducing doses to nearby organs at risk,” writes author Shahed Badiyan. The article appears in the journal Translational Lung Cancer Research.

Sources:

Badiyan, SN, et al, “Proton beam therapy for malignant pleural mesothelioma”, April, 2018, Translational Lung Cancer Research, pp. 189-198

“PBS, the Future of Proton Therapy”, July 3, 2007, Proton Therapy Today

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…